Virpax Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol VRPX, has announced a significant change in its executive leadership. On September 27, 2024, the company's Board of Directors appointed Katharyn Field, an existing member of the Board, to the position of Vice President and principal executive officer. The appointment took effect immediately. Virpax Pharmaceuticals, which is classified as an emerging growth company, has confirmed that Field will continue her duties as a member of the Board alongside her new executive role. This development was formally reported in a Form 8-K filing with the United States Securities and Exchange Commission, with the report signed by Katharyn Field on October 3, 2024.

Virpax Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol VRPX, has announced a significant change in its executive leadership. On September 27, 2024, the company's Board of Directors appointed Katharyn Field, an existing member of the Board, to the position of Vice President and principal executive officer. The appointment took effect immediately. Virpax Pharmaceuticals, which is classified as an emerging growth company, has confirmed that Field will continue her duties as a member of the Board alongside her new executive role. This development was formally reported in a Form 8-K filing with the United States Securities and Exchange Commission, with the report signed by Katharyn Field on October 3, 2024.